ArticleDrugs - real world outcomes2026
Use of Carbimazole, Methimazole and Propylthiouracil in Women of Childbearing Age and Exposed Pregnancies in Germany: A Population-Based Study.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHyperthyroidism during pregnancy is associated with maternal, obstetric and fetal complications. Antithyroid drugs (ATDs) including carbimazole (CMZ), methimazole (MMI) and propylthiouracil (PTU) are the main pharmacotherapies for hyperthyroidism. Exposure to CMZ and MMI during the first trimester was associated with birth defects, while PTU is assumed to be the safer alternative.
objectiveTo calculate the prescription prevalences of ATDs in women of childbearing age over time and to describe pregnancies occurring after or during ATD use.
methodsUsing the GePaRD database (claims data; 20% of the German population), we conducted year-wise cross-sectional studies for the period 2004-2020 to calculate prescription prevalences of CMZ, MMI and PTU in females aged 13-49 years. In longitudinal analyses, we included all women with any ATD dispensing between 2005 and 2020 aged 13-49 years at the first dispensing. We identified pregnancies occurring in this cohort and described ATD use before and during pregnancy.
resultsThe age-standardized prescription prevalence of ATDs decreased by 32.1% between 2004 (2.71 per 1000) and 2020 (1.84 per 1000). This decrease was attributable to CMZ (2004: 1.40 per 1000; 2020: 0.76 per 1000; relative decrease: 45.7%) and MMI (2004: 1.25 per 1000; 2020: 0.99 per 1000; relative decrease: 20.8%). In the cohort including 9723 women, 13,586 pregnancies were observed, of which 67% (n = 9140) occurred after ATD use. In 16.2% of the pregnancies (n = 2203), ATD use overlapped with pregnancy onset. The proportion exposed to CMZ/MMI at pregnancy onset decreased from 30.7% in 2005 to 10.9% in 2020. In 16.5% of pregnancies (n = 2243), ATD use was started during pregnancy.
conclusionThe prescription prevalence of ATD overall and specifically of CMZ/MMI in girls and women of childbearing age decreased between 2005 and 2020 in Germany. The decrease in exposure to CMZ/MMI at pregnancy onset indicates that physicians became increasingly aware of the potential risks of CMZ/MMI to the unborn child.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.